IRIS Registry data showed no change in anti-VEGF frequency, vision, or retinal thickness after patients with DME began a GLP-1RA.
News|Articles|October 7, 2026
Eyes on September 2026: ESCRS insights, gene therapy wins, and the push to treat myopia as a disease
Author(s)Martin David Harp
September was one of the busiest months of the year in eye care—From ESCRS to Eyecon
Advertisement
Advertisement
ESCRS 2026 brought thousands of anterior segment specialists to London, EyeCon 2026 put optometrists and ophthalmologists at the same table, and a steady stream of trial readouts and regulatory decisions kept the pipeline moving. Here is what our editors and contributors covered.
Related to this article
Murtaza K. Adam, MD, shares pearls on haptic docking, patient selection, and preventing complications with the Yamane technique.
Anat Galor, MD, MSPH, discusses subtyping dry eye, emerging diagnostic tools, and when to consider oral neuromodulation.
Interim 48-month data show 86% of patients with glaucoma or ocular hypertension remain off topical drops after a single cataract procedure, although the drop-free rate has eased from earlier timepoints.
Jordi Monés, MD, PhD, explains why RP and Stargardt data support testing son-vec to restore vision in advanced GA.
David F. Chang, MD, shares how to set realistic refractive IOL expectations and streamline patient counseling.
LUGANO missed its visual noninferiority endpoint for the vorolanib insert vs aflibercept in nAMD despite comparable anatomic control. Regillo attributes the gap partly to 9 outliers with vision loss unrelated to nAMD.
At AAO 2026, Adam, MD, shares Yamane technique pearls, from docking the trailing haptic to preventing tilt and haptic exposure.
Advertisement
Advertisement